Teleflex (NYSE:TFX) Price Target Increased to $240.00 by Analysts at Truist Financial

Teleflex (NYSE:TFX) had its target price upped by Truist Financial from $235.00 to $240.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has a “hold” rating on the medical technology company’s stock. Truist Financial’s price target points to a potential upside of 4.21% from the stock’s current price.

Several other equities analysts have also recently commented on TFX. Piper Sandler raised shares of Teleflex from a “neutral” rating to an “overweight” rating and raised their target price for the company from $205.00 to $245.00 in a research note on Monday, July 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Teleflex in a research note on Friday, May 3rd. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $263.14.

Teleflex Stock Up 0.4 %

Teleflex stock opened at $230.30 on Tuesday. The stock has a market cap of $10.85 billion, a price-to-earnings ratio of 36.97, a PEG ratio of 2.13 and a beta of 1.13. The company has a current ratio of 2.51, a quick ratio of 1.41 and a debt-to-equity ratio of 0.37. The company’s 50-day moving average price is $211.00 and its two-hundred day moving average price is $223.14. Teleflex has a 52 week low of $177.63 and a 52 week high of $262.97.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, May 2nd. The medical technology company reported $3.21 EPS for the quarter, beating the consensus estimate of $3.07 by $0.14. The firm had revenue of $737.80 million for the quarter, compared to analysts’ expectations of $726.85 million. Teleflex had a net margin of 9.82% and a return on equity of 14.78%. Teleflex’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the company earned $3.09 EPS. On average, analysts expect that Teleflex will post 13.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Kentucky Retirement Systems increased its position in shares of Teleflex by 1.1% in the fourth quarter. Kentucky Retirement Systems now owns 3,760 shares of the medical technology company’s stock worth $938,000 after acquiring an additional 42 shares in the last quarter. Venturi Wealth Management LLC increased its position in shares of Teleflex by 33.3% in the fourth quarter. Venturi Wealth Management LLC now owns 184 shares of the medical technology company’s stock worth $46,000 after acquiring an additional 46 shares in the last quarter. KBC Group NV increased its position in shares of Teleflex by 1.8% in the fourth quarter. KBC Group NV now owns 3,173 shares of the medical technology company’s stock worth $791,000 after acquiring an additional 55 shares in the last quarter. Lindbrook Capital LLC increased its position in shares of Teleflex by 75.3% in the fourth quarter. Lindbrook Capital LLC now owns 135 shares of the medical technology company’s stock worth $34,000 after acquiring an additional 58 shares in the last quarter. Finally, Empirical Finance LLC increased its position in shares of Teleflex by 3.9% in the first quarter. Empirical Finance LLC now owns 1,564 shares of the medical technology company’s stock worth $354,000 after acquiring an additional 58 shares in the last quarter. 95.62% of the stock is owned by hedge funds and other institutional investors.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.